These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 22349484)

  • 21. [USE OF STATINS IN PATIENTS WITH CHRONIC KIDNEY DISEASE TO PREVENT CARDIOVASCULAR DISEASE].
    Zavidić T; Lodeta B; Lovrinić Đ
    Acta Med Croatica; 2016 Dec; 70(4-5):301-7. PubMed ID: 29087163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dyslipidemia, malnutrition, inflammation, cardiovascular disease and mortality in chronic kidney disease.
    Peev V; Nayer A; Contreras G
    Curr Opin Lipidol; 2014 Feb; 25(1):54-60. PubMed ID: 24345987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis.
    Su X; Zhang L; Lv J; Wang J; Hou W; Xie X; Zhang H
    Am J Kidney Dis; 2016 Jun; 67(6):881-92. PubMed ID: 26905361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ESRD-induced dyslipidemia-Should management of lipid disorders differ in dialysis patients?
    Moradi H; Streja E; Vaziri ND
    Semin Dial; 2018 Jul; 31(4):398-405. PubMed ID: 29707830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The lipid story in chronic kidney disease: a long story with a happy end?
    Kujawa-Szewieczek A; Więcek A; Piecha G
    Int Urol Nephrol; 2013 Oct; 45(5):1273-87. PubMed ID: 23054316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipid changes and statins in chronic renal insufficiency.
    Ritz E; Wanner C
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S226-30. PubMed ID: 17130266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants.
    Barylski M; Nikfar S; Mikhailidis DP; Toth PP; Salari P; Ray KK; Pencina MJ; Rizzo M; Rysz J; Abdollahi M; Nicholls SJ; Banach M;
    Pharmacol Res; 2013 Jun; 72():35-44. PubMed ID: 23542730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.
    Vaziri ND; Norris KC
    Blood Purif; 2013; 35(1-3):31-6. PubMed ID: 23343544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin Renal Evaluation Trial (FRET).
    Inoue T; Ikeda H; Nakamura T; Abe S; Taguchi I; Kikuchi M; Toyoda S; Miyazono M; Kishi T; Sanai T; Node K
    Intern Med; 2011; 50(12):1273-8. PubMed ID: 21673461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atorvastatin improves tubular status in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study.
    Renke M; Tylicki L; Rutkowski P; Neuwelt A; Larczyński W; Ziętkiewicz M; Aleksandrowicz E; Lysiak-Szydłowska W; Rutkowski B
    Acta Biochim Pol; 2010; 57(4):547-52. PubMed ID: 21079818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Statins on Renal Outcome in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis.
    Sanguankeo A; Upala S; Cheungpasitporn W; Ungprasert P; Knight EL
    PLoS One; 2015; 10(7):e0132970. PubMed ID: 26151753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidemiology of dyslipidemia in chronic kidney disease.
    Iseki K
    Clin Exp Nephrol; 2014 Apr; 18(2):185-8. PubMed ID: 24408220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects and Safety of Statin and Ezetimibe Combination Therapy in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
    Lin YC; Lai TS; Wu HY; Chou YH; Chiang WC; Lin SL; Chen YM; Chu TS; Tu YK
    Clin Pharmacol Ther; 2020 Oct; 108(4):833-843. PubMed ID: 32320058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statin use in patients with diabetes and kidney disease: the Japanese experience.
    Koya D; Campese VM
    J Atheroscler Thromb; 2013; 20(5):407-24. PubMed ID: 23518468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of dyslipidemia in patients with metabolic syndrome and chronic kidney disease].
    Monhart V
    Vnitr Lek; 2009; 55(7-8):671-8. PubMed ID: 19731874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Statins on Renal Function in Chronic Kidney Disease Patients.
    Hu PJ; Wu MY; Lin TC; Chen TT; Wu YC; Su SL; Lu KC; Chen JS; Sung FC; Lee CT; Yang Y; Hwang SJ; Wang MC; Hsu YH; Chiou HY; Wong CS; Lin YF
    Sci Rep; 2018 Nov; 8(1):16276. PubMed ID: 30390007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dyslipidemia in children with CKD: should we treat with statins?
    Tullus K
    Pediatr Nephrol; 2012 Mar; 27(3):357-62. PubMed ID: 21487766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical assessment and management of dyslipidemia in patients with chronic kidney disease.
    Nitta K
    Clin Exp Nephrol; 2012 Aug; 16(4):522-9. PubMed ID: 22722878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence.
    Kanbay M; Turgut F; Covic A; Goldsmith D
    J Nephrol; 2009; 22(5):598-609. PubMed ID: 19809992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Chronic Kidney Disease on Risk for Vascular Events.
    Fan J; Salameh H
    Curr Vasc Pharmacol; 2016; 14(5):409-414. PubMed ID: 27456102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.